Find Reports

Select Report Type

Reimbursement Review

Displaying 301 - 325 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Adult Classical Hodgkin Lympho...			Final Report	Adult Classical Hodgkin Lymphoma		Complete		Feb 2, 2022	PH0007-000
isatuximab	Sarclisa	isatuximab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Multiple myeloma	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2021	Jan 28, 2022	PC0256-000
daratumumab	Darzalex	daratumumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Light chain (AL) amyloidosis	Reimburse with clinical criteria and/or conditions	Complete	Jul 15, 2021	Jan 28, 2022	PC0257-000
sacituzumab govitecan	Trodelvy	sacituzumab govitecan	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions	Locally advanced or metastatic triple-negative breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Jun 30, 2021	Jan 27, 2022	PC0254-000
nivolumab	Opdivo	nivolumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report	Esophageal or gastroesophageal junction cancer	Reimburse with clinical criteria and/or conditions	Complete	Jul 7, 2021	Jan 26, 2022	PC0253-000
alpelisib	Piqray	alpelisib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Advanced or Metastatic Breast Cancer	Do not reimburse	Complete	Apr 21, 2021	Jan 26, 2022	PC0247-000
pertuzumab	Perjeta	pertuzumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Early stage breast cancer	Do not reimburse	Complete	Apr 14, 2021	Jan 25, 2022	PC0241-000
mecasermin	Increlex	mecasermin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Severe primary insulin-like growth factor-1 deficiency	Reimburse with clinical criteria and/or conditions	Complete	Jun 14, 2021	Jan 21, 2022	SR0692-000
triheptanoin	Dojolvi	triheptanoin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Long-chain fatty acid oxidation disorders	Reimburse with clinical criteria and/or conditions	Complete	Mar 31, 2021	Jan 21, 2022	SR0684-000
estradiol	Imvexxy	estradiol	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Dyspareunia	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2021	Jan 20, 2022	SR0694-000
osimertinib	Tagrisso	osimertinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Non-small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 24, 2021	Jan 10, 2022	PC0246-000
enfortumab vedotin	Padcev	enfortumab vedotin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Locally advanced or metastatic urothelial carcinoma	Reimburse with clinical criteria and/or conditions	Complete	Jun 23, 2021	Jan 6, 2022	PC0251-000
zanubrutinib	Brukinsa	zanubrutinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Waldenström’s macroglobulinemia	Reimburse with clinical criteria and/or conditions	Complete	May 21, 2021	Dec 21, 2021	PC0248-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Esophageal carcinoma, gastroesophageal junction adenocarcinoma	Reimburse with clinical criteria and/or conditions	Complete	May 26, 2021	Dec 20, 2021	PC0250-000
galcanezumab	Emgality	galcanezumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Prevention of migraine	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2021	Dec 15, 2021	SR0693-000
macitentan and tadalafil	Opsynvi	macitentan and tadalafil	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder Feedback on Draft Recommendation	Pulmonary arterial hypertension	Reimburse with clinical criteria and/or conditions	Complete	May 20, 2021	Dec 14, 2021	SR0690-000
luspatercept	Reblozyl	luspatercept	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Myelodysplastic syndromes-associated anemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 28, 2021	Dec 7, 2021	SR0670-000
chlormethine hydrochloride	Ledaga	chlormethine hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	T-cell lymphoma	Do not reimburse	Complete	Dec 21, 2020	Nov 24, 2021	PC0242-000
tucatinib	Tukysa	tucatinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Advanced or Metastatic Breast Cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 26, 2021	Nov 17, 2021	PC0243-000
idecabtagene vicleucel	Abecma	idecabtagene vicleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, and Ethics combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Multiple myeloma	Do not reimburse	Complete	Dec 16, 2020	Nov 12, 2021	PG0240-000
Colorectal Cancer			Final Report	Colorectal Cancer		Complete		Nov 12, 2021	PH0005-000
Trientine Hydrochloride	MAR-Trientine	Trientine Hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Wilson's Disease	Reimburse with clinical criteria and/or conditions	Complete	Apr 19, 2021	Nov 11, 2021	SR0680-000
romosozumab	Evenity	romosozumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Osteoporosis, postmenopausal women	Reimburse with clinical criteria and/or conditions	Complete	Feb 1, 2021	Nov 11, 2021	SR0676-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Classical Hodgkin lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Jan 29, 2021	Nov 1, 2021	PC0236-000
azacitidine	Onureg	azacitidine	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Acute myeloid leukemia	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2021	Oct 20, 2021	PC0245-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 301 - 325 of 602

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Radioiodine Resensitization for Radioiodine Refractory Metastatic Differentiated Thyroid Cancer	Radioiodine Resensitization for Radioiodine Refractory Metastatic Differentiate…	Apr 15, 2022	Rapid Review	Completed	RC1419-000
Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder	Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder	Apr 14, 2022	Rapid Review	Completed	RC1420-000
Risk Factors and Preventive Interventions for Post‒COVID-19 condition		Apr 11, 2022	Systematic Review	Complete	RE0039-000
Metered-Dose Inhalers for Medical Cannabis Use	Metered-Dose Inhalers for Medical Cannabis Use	Apr 11, 2022	Rapid Review	Completed	RC1417-000
Robotic-Assisted Surgical Systems for Hip Arthroplasty	Robotic-Assisted Surgical Systems for Hip Arthroplasty	Apr 6, 2022	Rapid Review	Completed	RC1412-000
Therapeutic Mattresses for Chronic Pain	Therapeutic Mattresses for Chronic Pain	Apr 6, 2022	Rapid Review	Completed	RC1415-000
Dementia Concerns and Considerations: Our Panel of People With Lived Experience	Dementia Concerns and Considerations: Our Panel of People With Lived Experience	Apr 1, 2022	Technology Review	Completed	EH0107-000 - HC0022-000
Intraocular Lenses for Infants with Aphakia	Intraocular Lenses for Infants With Aphakia - Health Technology Review Intraocular Lenses for Infants With Aphakia - Project Protocol (Amended Report)Intraocular Lenses for Infants With Aphakia - Project Protocol (Superseded Repo…In Brief: Intraocular Lenses for Infants With Aphakia	Mar 31, 2022	Systematic Review	Complete	RE0036-000
Folate Testing in People With Suspected Folate Deficiency	Folate Testing in People With Suspected Folate Deficiency	Mar 28, 2022	Rapid Review	Completed	RC1414-000
Vitamin B12 Testing in People with Suspected Vitamin B12 Deficiency	Vitamin B12 Testing in People with Suspected Vitamin B12 Deficiency	Mar 24, 2022	Rapid Review	Completed	RC1413-000
Adalimumab for the Treatment of Pediatric Populations With Non-Infectious Uveitis	Adalimumab for the Treatment of Pediatric Populations With Non-Infectious Uveit…	Mar 16, 2022	Rapid Review	Completed	RD0064-000
Robotic-Assisted Surgical Systems for Knee Arthroplasty	Robotic-Assisted Surgical Systems for Knee Arthroplasty	Mar 16, 2022	Rapid Review	Completed	RC1411-000
Custom-Made Foot Orthotics for People with Lower Limb Conditions	Custom-Made Foot Orthotics for People with Lower Limb Conditions	Feb 18, 2022	Rapid Review	Completed	RC1410-000
Anakinra Therapy for Hemophagocytic Lymphohistiocytosis	Anakinra Therapy for Hemophagocytic Lymphohistiocytosis	Feb 16, 2022	Rapid Review	Completed	RC1409-000
Temperature Management in Patients Post-Cardiac Arrest	Temperature Management in Patients Post-Cardiac Arrest	Feb 16, 2022	Rapid Review	Completed	RC1407-000
Antibiotic Solutions for Surgical Irrigation	Antibiotic Solutions for Surgical Irrigation	Feb 7, 2022	Rapid Review		RC1408-000
Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19	Nirmatrelvir and Ritonavir (Paxlovid) for Mild to Moderate COVID-19	Jan 28, 2022	Technology Review	Completed	HD0007-000
Adalimumab for the Treatment of Adults With Non-Infectious Uveitis	Adalimumab for the Treatment of Adults With Non-Infectious Uveitis	Jan 24, 2022	Rapid Review	Completed	RD0063-000
Orthopedic Footwear for People With Lower-Limb Conditions	Orthopedic Footwear for People With Lower-Limb Conditions	Jan 24, 2022	Rapid Review	Completed	RC1406-000
The Small House Model for Long-Term Care	The Small House Model for Long-Term Care In Brief: The Small House Model to Support Older Adults in Long-Term Care	Jan 20, 2022	Environmental Scan	Completed	ES0359-000
Pharmacogenomic Testing in Depression: A 2021 Update	Pharmacogenomic Testing in Depression: A 2021 Update	Jan 18, 2022	Rapid Review	Completed	RC1403-000
Evaluations of Virtual Care	Evaluations of Virtual Care	Jan 12, 2022	Environmental Scan	Complete	ES0358-000
Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma	Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Prior to Autol…	Jan 10, 2022	Rapid Review	Completed	RC1404-000
Floatation Therapy for Physical Conditions	Floatation Therapy for Physical Conditions	Jan 10, 2022	Rapid Review	Completed	RC1398-000
Clinical Effectiveness of Opioid Substitution Treatment	Clinical Effectiveness of Opioid Substitution Treatment	Jan 10, 2022	Rapid Review	Completed	RC1405-000 - RB1604-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 301 - 325 of 2138

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Pembrolizumab		Recommendation and Reason Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	PX0346-000
Nivolumab and Ipilimumab		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic combined Report Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	PX0347-000
Nab-paclitaxel		Recommendation and reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input	Oct 30, 2024	Reimbursement Review		Complete	PX0348-000
bevacizumab and lomustine		Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input - Clinicians Stakeholder Input - Industry Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0318-000
Review of Guidelines on Bupropion for Depression		Review of Guidelines on Bupropion for Depression	Oct 30, 2024	Health Technology Review	Rapid Review	Completed	RC1558-000
GLP-1 Receptor Agonists and Self-Harm			Oct 29, 2024	Health Technology Review	Observational Study	Active	OS0009-000
relugolix		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation Patient and Clinician Group input	Oct 29, 2024	Reimbursement Review		Complete	PC0342-000
Gabapentin for Seizures		Gabapentin for Seizures	Oct 25, 2024	Health Technology Review	Rapid Review	Completed	RC1557-000
Early Biologic Treatment for Inflammatory Bowel Disease		Early Biologic Treatment for Inflammatory Bowel Disease	Oct 25, 2024	Health Technology Review	Rapid Review	Completed	RC1552-000
The Utilization of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 22, 2024	Health Technology Review	Technology Review	Active	HC0094-000
Airway Management in Out-of-Hospital Emergencies		Airway Management in Out-of-Hospital Emergencies	Oct 21, 2024	Health Technology Review	Rapid Review	Completed	RC1555-000
CRISPR Technologies for In Vivo and Ex Vivo Gene Editing	Our Horizon Scan provides an overview of CRISPR technologies and their current and potential roles in health care.	Final Report	Oct 21, 2024	Horizon Scan	Emerging Health Technologies	Completed	EH00127-000 - HC0092-000
BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis		BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis	Oct 21, 2024	Health Technology Review	Rapid Review	Completed	RC1549-000
datopotamab deruxtecan			Oct 18, 2024	Reimbursement Review		Cancelled	PC0384-000
Re-treatment With Immune Checkpoint Inhibitors: Utilization Analysis			Oct 16, 2024	Health Technology Review	Technology Review	In Progress	HC0093-000
bimekizumab		Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 10, 2024	Reimbursement Review		Complete	SR0809-000
leniolisib			Oct 10, 2024	Reimbursement Review		Suspended	SR0792-000
metreleptin		Recommendations and Reasons Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 10, 2024	Reimbursement Review		Complete	SR0784-000
The Effectiveness of PCSK9 Inhibitors in Familial Hypercholesterolemia			Oct 10, 2024	Health Technology Review	Observational Study	Active	OS0011-000
Prostate Cancer		Final Report	Oct 9, 2024	Reimbursement Review	Provisional Funding Algorithm	Active	PH0050-000
Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer		Bilateral Opportunistic Salpingectomy to Reduce the Incidence of Ovarian Cancer	Oct 4, 2024	Health Technology Review	Summary with Critical Appraisal	Completed	RC1550-000
insulin icodec		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Oct 3, 2024	Reimbursement Review		Complete	SR0790-000
Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant		Lenvatinib for the Treatment of Hepatocellular Carcinoma After Liver Transplant	Oct 2, 2024	Health Technology Review	Rapid Review	Completed	RC1553-000
etranacogene dezaparvovec		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group Input	Sep 26, 2024	Reimbursement Review		Complete	SG0805-000
nivolumab		Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Sep 26, 2024	Reimbursement Review		Complete	PC0339-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81